Esperion Therapeutics, Inc. (ESPR.D)
- Sector
- Pharmaceuticals
- Last price
- $3.18
- As of
Kresmion compiles this page from ESPR.D's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Esperion Therapeutics, Inc. (ESPR.D): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-07-13.
See the full ESPR.D dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ESPR.D on one page. Preview it with sample data, then open it live with a free account.
Preview the ESPR.D dossierActive signals for ESPR.D
No recent signals on ESPR.D in the last 180 days.
FREE, NO ACCOUNT
Every signal on ESPR.D, as it fires
New filings, 13F moves and cross asset signals on ESPR.D land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ESPR.D (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 29664W105 · 2026Q2 | $22.5M | 0.02% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 29664W105 · 2026Q2 | $7M | 0.00% | , |
| SOROS FUND MANAGEMENT LLCCUSIP 29664W105 · 2026Q2 | $2.4M | 0.03% | , |
| CITADEL ADVISORS LLCCUSIP 29664W105 · 2026Q2 | $1.5M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 29664W105 · 2026Q2 | $506K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ESPR.D
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
ESPR.D against its peers
ESPR.D's operating margin of 15.0% ranks in the 68th percentile of 19 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-03-31 and 2026-06-30.
| Metric | ESPR.D | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 403M USD | 411M USD | 48 | 19 |
| Gross margin | n/a | 73.3% | n/a | 11 |
| Operating margin | 15.0% | 2.6% | 68 | 19 |
| Net margin | -5.6% | 0.5% | 38 | 19 |
| Return on equity | n/a | -9.3% | n/a | 23 |
| P / E | n/a | 13.6x | n/a | 9 |
Peers (25): ALMS, COLL, ANRO, AMPH, ACRS, NKTR, OMER, PCRX, INVA, GPCR, PAHC, OCUL, ANIP, NUVB, AVIR, XERS, TRVI, HRMY, FULC, BHC, SUPN, ACB, BIOA, SIGA, TARS. Fiscal periods ending between 2025-03-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (ESPR.D: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow ESPR.D on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to ESPR.D for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.